Table 3. PCR-adjusted treatment response of study patients treated with artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL)
Treatment responses | Artesunate-amodiaquine | Artemether-lumefantrine | ||||
|---|---|---|---|---|---|---|
Malabo (N = 88) n (%) | Bata (N = 88) n (%) | Ebibeyin (N = 88) n (%) | Malabo (N = 50) n (%) | Bata (N = 88) n (%) | Ebibeyin (N = 88) n (%) | |
PCR-adjusted WHO methodology | ||||||
LCF | 0 | 0 | 0 | 0 | 0 | 0 |
LPF | 0 | 0 | 1 (1.4) | 2 (4.9) | 0 | 5 (7.6) |
ACPR | 67 (100) | 78 (100) | 71 (98.6) | 39 (95.1) | 81 (100) | 61 (92.4) |
Total per-protocol | 67 | 78 | 72 | 41 | 81 | 66 |
Lost follow-up/withdrawn | 21 (23.9) | 7 (8) | 8 (9.1) | 8 (16) | 3 (3.4) | 5 (5.7) |
New infection | 0 | 3 (3.4) | 8 (9.1) | 1 (2) | 4 (4.5) | 17 (19.3) |
Kaplan Meier: cure rate | 67 (100) | 78 (100) | 71 (98.7) | 39 (95.2) | 81 (100) | 61 (93.7) |
PCR-adjusted 2/3 algorithm | ||||||
LCF | 0 | 0 | 1 (1.3) | 0 | 0 | 12 (16.4) |
LPF | 0 | 0 | 4 (5.3) | 3 (4.9) | 0 | 5 (7.6) |
ACPR | 67 (100) | 78 (100) | 71 (93.4) | 39 (92.9) | 81 (100) | 61 (83.6) |
Total per-protocol | 67 | 78 | 76 | 42 | 81 | 73 |
Lost follow-up/withdrawn | 21 (23.9) | 7 (8) | 8 (9.1) | 8 (16) | 3 (3.4) | 5 (5.7) |
New infection | 0 | 2 (2.3) | 2 (2.6) | 0 | 2 (2.3) | 7 (7.9) |
Undetermined | 0 | 1 (1.1) | 2 (2.6) | 0 | 2 (2.3) | 3 (3.4) |
Kaplan Meier: cure rate | 100 | 100 | 93.6 | 92.9 | 100 | 84.5 |